PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1453897
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1453897
Schizoaffective Disorders Market Forecasts to 2030 - Global Analysis By Type (Medication and Psychotherapy), Cause, Application, End User, and By Geography
According to Stratistics MRC, the Global Schizoaffective Disorders Market is accounted for $7.6 billion in 2023 and is expected to reach $10.7 billion by 2030 growing at a CAGR of 4.9% during the forecast period. Schizoaffective disorder is a chronic mental health condition characterized by a combination of symptoms of schizophrenia, such as hallucinations or delusions, and mood disorders, such as depression or mania. Individuals with schizoaffective disorder typically experience periods of psychosis, during which they may have difficulty distinguishing between what is real and what is not, along with significant mood disturbances. Treatment usually involves a combination of antipsychotic medications, mood stabilizers, and psychotherapy to manage symptoms and improve functioning.
According to WHO, in 2018, 970 million individuals worldwide, or 1 in every eight persons, had a mental illness, including anxiety and depressive disorders. Now, around 19.86% of adults are experiencing a mental illness worldwide.
Market Dynamics:
Driver:
Increasing awareness and diagnosis
Raising awareness and enhancing diagnosis in the market is crucial for timely intervention and improved patient outcomes. Through targeted educational campaigns, healthcare professionals can better recognize the nuanced symptoms, facilitating early identification and appropriate treatment strategies. Additionally, community outreach programs can empower individuals and families to seek help, reducing stigma and fostering a supportive environment for those affected.
Restraint:
Stigma associated with mental illness
Despite strides in awareness, misconceptions persist, hindering acceptance and access to treatment. Individuals with this disorder often face social ostracization and discrimination, impeding their integration into society and employment opportunities. This stigma not only exacerbates their psychological distress but also deters them from seeking help, perpetuating a cycle of isolation and untreated symptoms. Thus, this is the major factor impeding the growth of the market.
Opportunity:
Focus on personalized medicine
Personalized medicine holds immense promise in the treatment landscape of this disorder. Tailored approaches, integrating genetic, neurobiological, and environmental factors, offer a profound shift from traditional one-size-fits-all treatments. Precision medicine enables clinicians to select therapies based on individual patient characteristics, enhancing efficacy and minimizing adverse effects. Hence, these are the factors propelling the growth of the market.
Threat:
High cost of treatment
The treatment of schizoaffective disorder presents significant financial burdens, with costs often reaching exorbitant levels. This encompasses expenses related to medication, therapy, hospitalizations, and ongoing psychiatric care. Additionally, indirect costs such as lost productivity and social support further escalate the financial strain on individuals and their families. Therefore, the high cost of managing schizoaffective disorder is the factor hampering the growth of the market.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the market, causing disruptions in treatment access and patient care. Lockdown measures, reduced healthcare facility capacities, and prioritization of resources towards COVID-19 management led to delays in diagnosis, treatment initiation, and therapy adjustments for schizoaffective disorder patients. Telehealth emerged as a vital tool for remote consultations, but disparities in digital access and quality of care persisted.
The psychotherapy segment is expected to be the largest during the forecast period
The psychotherapy segment is expected to be the largest during the forecast period. Psychotherapy plays a crucial role in the management of Schizoaffective Disorder, offering a comprehensive approach alongside medication. Cognitive-behavioral therapy (CBT), supportive therapy, and family therapy are commonly utilized modalities. They aim to enhance coping strategies, improve social functioning, and facilitate medication adherence.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals catering to the Schizoaffective Disorders market offer specialized care tailored to individuals experiencing this complex mental health condition. These facilities provide comprehensive services, including diagnosis, medication management, therapy, and support programs, aimed at addressing the unique needs of patients with schizoaffective disorders.
Region with largest share:
North America is projected to hold the largest market share during the forecast period driven by increasing awareness, improved diagnostic techniques, and advancements in treatment options. Pharmaceutical companies are investing in research and development to introduce novel therapies addressing both psychotic and affective symptoms, enhancing patient outcomes. Additionally, supportive government initiatives and healthcare reforms further propel market expansion.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period. The availability and accessibility of mental health services vary widely across countries in the region. Government policies and regulations regarding mental health care, including funding for mental health services and support for research and development of new treatment options, can significantly impact the market for schizoaffective disorder treatment in the region.
Key players in the market
Some of the key players in Schizoaffective Disorders market include Abbott Pharmaceuticals, AstraZeneca PLC, Bright Quest, Bristol Myers Squibb, Cascade Behavioural Health Hospital, Ciba Pharmaceuticals, Cleveland Clinic, Covington Behavioural Health Hospital, Delta Medical Center, Elan Pharmaceuticals, Eli Lilly and Company, Janssen cilag Pvt. Ltd., Johnson and Johnson, Merz Pharma GmbH & Co. And Pfizer.
Key Developments:
In January 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labeling for its dorsal root ganglion (DRG) stimulation therapy, the Proclaim(TM) DRG neurostimulation system, which allows patients to receive full-body MRI scans while implanted with the device.
In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.
Types Covered:
- Medication
- Psychotherapy
Causes Covered:
- Genetic Factors
- Environmental Factors
- Chemical Factors
Applications Covered:
- Devices
- Drugs
- Diagnostics
- Other Applications
End Users Covered:
- Online Pharmacy
- Hospitals
- Retail pharmacy
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Schizoaffective Disorders Market, By Type
- 5.1 Introduction
- 5.2 Medication
- 5.2.1 Mood stabilizers
- 5.2.2 Antipsychotics
- 5.2.3 Antidepressants
- 5.3 Psychotherapy
- 5.3.1 Individual Therapy
- 5.3.2 Group Therapy
6 Global Schizoaffective Disorders Market, By Cause
- 6.1 Introduction
- 6.2 Genetic Factors
- 6.3 Environmental Factors
- 6.4 Chemical Factors
7 Global Schizoaffective Disorders Market, By Application
- 7.1 Introduction
- 7.2 Devices
- 7.3 Drugs
- 7.4 Diagnostics
- 7.5 Other Applications
8 Global Schizoaffective Disorders Market, By End User
- 8.1 Introduction
- 8.2 Online Pharmacy
- 8.3 Hospitals
- 8.4 Retail pharmacy
- 8.5 Other End Users
9 Global Schizoaffective Disorders Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Abbott Pharmaceuticals
- 11.2 AstraZeneca PLC
- 11.3 Bright Quest
- 11.4 Bristol Myers Squibb
- 11.5 Cascade Behavioural Health Hospital
- 11.6 Ciba Pharmaceuticals
- 11.7 Cleveland Clinic
- 11.8 Covington Behavioural Health Hospital
- 11.9 Delta Medical Center
- 11.10 Elan Pharmaceuticals
- 11.11 Eli Lilly and Company
- 11.12 Janssen cilag Pvt. Ltd.
- 11.13 Johnson and Johnson
- 11.14 Merz Pharma GmbH & Co.
- 11.15 Pfizer
List of Tables
- Table 1 Global Schizoaffective Disorders Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
- Table 4 Global Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
- Table 5 Global Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
- Table 6 Global Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
- Table 7 Global Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
- Table 8 Global Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
- Table 9 Global Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
- Table 10 Global Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
- Table 11 Global Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
- Table 12 Global Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
- Table 13 Global Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
- Table 14 Global Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
- Table 15 Global Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
- Table 16 Global Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
- Table 17 Global Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
- Table 18 Global Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 19 Global Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
- Table 20 Global Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 21 Global Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 22 Global Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
- Table 23 Global Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 24 North America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
- Table 25 North America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
- Table 26 North America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
- Table 27 North America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
- Table 28 North America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
- Table 29 North America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
- Table 30 North America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
- Table 31 North America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
- Table 32 North America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
- Table 33 North America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
- Table 34 North America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
- Table 35 North America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
- Table 36 North America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
- Table 37 North America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
- Table 38 North America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
- Table 39 North America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
- Table 40 North America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
- Table 41 North America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 42 North America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
- Table 43 North America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 44 North America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 45 North America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
- Table 46 North America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 47 Europe Stain-Resistant Fabric Market Outlook, By Country (2021-2030) ($MN)
- Table 48 Europe Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
- Table 49 Europe Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
- Table 50 Europe Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
- Table 51 Europe Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
- Table 52 Europe Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
- Table 53 Europe Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
- Table 54 Europe Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
- Table 55 Europe Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
- Table 56 Europe Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
- Table 57 Europe Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
- Table 58 Europe Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
- Table 59 Europe Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
- Table 60 Europe Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
- Table 61 Europe Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
- Table 62 Europe Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
- Table 63 Europe Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
- Table 64 Europe Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 65 Europe Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
- Table 66 Europe Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 67 Europe Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 68 Europe Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
- Table 69 Europe Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 70 Asia Pacific Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
- Table 71 Asia Pacific Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
- Table 72 Asia Pacific Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
- Table 73 Asia Pacific Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
- Table 74 Asia Pacific Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
- Table 75 Asia Pacific Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
- Table 76 Asia Pacific Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
- Table 77 Asia Pacific Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
- Table 78 Asia Pacific Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
- Table 79 Asia Pacific Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
- Table 80 Asia Pacific Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
- Table 81 Asia Pacific Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
- Table 82 Asia Pacific Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
- Table 83 Asia Pacific Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
- Table 84 Asia Pacific Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
- Table 85 Asia Pacific Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
- Table 86 Asia Pacific Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
- Table 87 Asia Pacific Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 88 Asia Pacific Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
- Table 89 Asia Pacific Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 90 Asia Pacific Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 91 Asia Pacific Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
- Table 92 Asia Pacific Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 93 South America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
- Table 94 South America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
- Table 95 South America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
- Table 96 South America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
- Table 97 South America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
- Table 98 South America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
- Table 99 South America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
- Table 100 South America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
- Table 101 South America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
- Table 102 South America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
- Table 103 South America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
- Table 104 South America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
- Table 105 South America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
- Table 106 South America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
- Table 107 South America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
- Table 108 South America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
- Table 109 South America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
- Table 110 South America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 111 South America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
- Table 112 South America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 113 South America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 114 South America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
- Table 115 South America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 116 Middle East & Africa Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
- Table 117 Middle East & Africa Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
- Table 118 Middle East & Africa Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
- Table 119 Middle East & Africa Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
- Table 120 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
- Table 121 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
- Table 122 Middle East & Africa Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
- Table 123 Middle East & Africa Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
- Table 124 Middle East & Africa Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
- Table 125 Middle East & Africa Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
- Table 126 Middle East & Africa Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
- Table 127 Middle East & Africa Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
- Table 128 Middle East & Africa Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
- Table 129 Middle East & Africa Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
- Table 130 Middle East & Africa Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
- Table 131 Middle East & Africa Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
- Table 132 Middle East & Africa Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
- Table 133 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 134 Middle East & Africa Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
- Table 135 Middle East & Africa Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 136 Middle East & Africa Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 137 Middle East & Africa Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
- Table 138 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
